Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Cellular
A synthetic fragment studied in preclinical cellular research models.
Reviewed by Dr. James Whitfield, PharmD · Published · Last reviewed · For research use only.
Type
Synthetic peptide (Thymosin Beta-4 related)
Molecular formula
C212H350N56O78S
Molecular weight
~4,963 g/mol
CAS number
77591-33-4
Amino acids
43
Sequence
Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES
Modification
N-terminal acetylation. Two distinct molecules are marketed under this name: full-length Thymosin Beta-4 (Tβ4; 43 residues; CAS 77591-33-4) and the actin-binding fragment Ac-LKKTETQ (residues 17-23; CAS 885340-08-9). Most published in vivo and clinical research has examined the full-length peptide, not the short fragment; the two are studied as separate molecules.
Thymosin Beta-4 is the principal intracellular G-actin-sequestering peptide; the LKKTETQ motif is its actin-binding domain. It binds monomeric actin and modulates actin polymerization rather than acting through a cell-surface receptor.
Lyophilized
20°C
~24 months desiccated and protected from light.
Highly water-soluble; protect from light; aliquot; salt form affects exact mass.
Reviews
Kleinman HK, et al. (2023). Int Immunopharmacology
Sosne G, Berger EA. (2023). Int Immunopharmacol
Sosne G. (2018). Expert Opin Biol Ther
Reviews
Dubé KN, Smart N. (2018). Expert Opin Biol Ther
Kleinman HK, Sosne G. (2016). Vitam Horm
Sosne G, Kleinman HK. (2015). Invest Ophthalmol Vis Sci
Morris DC, et al. (2012). Ann NY Acad Sci
Goldstein AL, et al. (2012). Expert Opin Biol Ther
Crockford D, et al. (2010). Ann NY Acad Sci
Hannappel E. (2007). Ann NY Acad Sci
Goldstein AL, et al. (2005). Trends Mol Med
Clinical
Sosne G, et al. (2022). Int J Mol Sci
Sosne G, Ousler GW. (2015). Clin Ophthalmol
Sosne G, et al. (2015). Cornea
Ruff D, et al. (2010). Ann NY Acad Sci
ClinicalTrials.gov. ClinicalTrials.gov
ClinicalTrials.gov. ClinicalTrials.gov
ClinicalTrials.gov. ClinicalTrials.gov
ClinicalTrials.gov. ClinicalTrials.gov
ClinicalTrials.gov. ClinicalTrials.gov
ClinicalTrials.gov. ClinicalTrials.gov
ClinicalTrials.gov. ClinicalTrials.gov
ClinicalTrials.gov. ClinicalTrials.gov
ClinicalTrials.gov. ClinicalTrials.gov
ClinicalTrials.gov. ClinicalTrials.gov
Primary research
Kim S, Choi J, Kwon J. (2023). Molecules
Tan SH, et al. (2021). Theranostics
Kim S, Kwon J. (2018). Sci Rep
Li H, et al. (2018). J Gene Med
Kim J, Jung Y. (2017). Sci Rep
Hong Y, et al. (2017). Biochem Biophys Res Commun
Zhang J, et al. (2016). Neurobiol Dis
Cheng P, et al. (2014). Neuropharmacology
Conte E, et al. (2013). Eur J Clin Invest
Wang L, et al. (2012). Neurobiol Dis
Xiong Y, et al. (2012). J Neurosurg
Didry D, et al. (2012). EMBO J
Esposito S, et al. (2012). Drug Test Anal
Ho ENM, et al. (2012). J Chromatogr A
Smart N, et al. (2011). Nature
Morris DC, et al. (2010). Neuroscience
Zhang J, et al. (2009). Neuroscience
Smart N, et al. (2007). Nature
Philp D, et al. (2007). Ann NY Acad Sci
Philp D, et al. (2006). J Cell Physiol
Bock-Marquette I, et al. (2004). Nature
Philp D, et al. (2004). FASEB J
Irobi E, et al. (2004). EMBO J
Hertzog M, et al. (2004). Cell
Philp D, et al. (2003). FASEB J
Sosne G, et al. (2002). Exp Eye Res
Grant DS, et al. (1999). Angiogenesis
Malinda KM, et al. (1999). J Invest Dermatol
Malinda KM, et al. (1997). FASEB J
Weber A, et al. (1992). Biochemistry
Also known as: Thymosin beta-4 (full-length), Ac-LKKTETQ (fragment)
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
| Compound | Type | Molecular weight | CAS number |
|---|---|---|---|
| TB-500This page | Synthetic peptide (Thymosin Beta-4 related) | ~4,963 g/mol | 77591-33-4 |
| BPC-157 | Synthetic peptide (pentadecapeptide) | 1,419.5 g/mol | 137525-51-0 |
| Epithalon | Synthetic linear tetrapeptide | 390.35 g/mol | 307297-39-8 |
| SS-31 | Synthetic aromatic-cationic tetrapeptide (C-terminally amidated, mitochondria-targeted) | 639.8 g/mol | 736992-21-5 |
| BPC-157 + TB-500 + GHK-Cu + KPV | Peptide blend | — | — |
Comparison of laboratory reference specifications only. For research use only; not a therapeutic comparison.
Quality & methods